LRRK2 (Leucine-Rich Repeat Kinase 2)
Overview
Mermaid diagram (expand to render)
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">LRRK2</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>LRRK2</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Leucine-Rich Repeat Kinase 2</td>
</tr>
<tr>
<td class="label">Gene Location</td>
<td>12q12 (chromosome 12)</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Serine/threonine kinase</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q5S007" target="_blank">Q5S007</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">View in Atlas</a></td>
</tr>
</table>
LRRK2 (Leucine-Rich Repeat Kinase 2) is a large, multi-domain enzyme that functions as both a kinase and a GTPase. It is the most commonly mutated gene in familial [Parkinson's disease](/diseases/parkinsons-disease) and is also a risk factor for sporadic PD and other neurodegenerative conditions. LRRK2 regulates multiple cellular processes including vesicle trafficking, autophagy, lysosomal function, and immune responses. Pathogenic mutations typically increase kinase activity, leading to neuronal dysfunction and degeneration.
Structure and Domains
LRRK2 is a large 286 kDa protein (2,527 amino acids) with a complex multi-domain architecture:
- ARM (Armadillo) repeats: Protein-protein interaction domain at N-terminus
- ANK (Ankyrin) repeats: Additional scaffolding domain
- LRR (Leucine-Rich Repeat): Regulatory domain
- ROC (Ras of Complex): GTPase domain that binds and hydrolyzes GTP
- COR (C-terminal of ROC): Dimerization domain
- Kinase domain: Serine/threonine kinase catalytic core
- WD40 domain: C-terminal protein interaction domain
The ROC-COR-Kinase catalytic core represents the functional heart of the enzyme, with GTPase activity regulating kinase activity.
Cellular Functions
Vesicle Trafficking and Membrane Dynamics
LRRK2 localizes to membranous structures and regulates:
- Endocytic vesicle trafficking
- Golgi dynamics and secretory pathways
- Synaptic vesicle endocytosis
- Trans-Golgi network (TGN) function
The protein phosphorylates a subset of Rab GTPases (particularly Rab8A, Rab10, Rab29, Rab35), key regulators of vesicular transport, thereby modulating membrane trafficking throughout the cell.
Autophagy and Lysosomal Function
LRRK2 regulates autophagy at multiple levels:
- Autophagosome formation and maturation
- Lysosomal positioning and acidification
- Autophagy-lysosome fusion
- Mitophagy (selective autophagy of mitochondria)
Pathogenic mutations impair lysosomal degradation, leading to accumulation of damaged organelles and protein aggregates.
Immune Function
LRRK2 is highly expressed in immune cells (macrophages, microglia) and modulates:
- Inflammatory responses to pathogens
- Cytokine production
- Phagocytosis
- Interferon signaling
This immune function may explain why LRRK2 variants influence susceptibility to inflammatory diseases like Crohn's disease and leprosy.
Role in Parkinson's Disease
Genetic Mutations
LRRK2 mutations account for:
- 5-6% of familial Parkinson's disease
- 1-2% of sporadic cases globally
- Up to 40% of PD cases in certain populations (Ashkenazi Jews, North African Arabs)
The most common pathogenic mutation is
G2019S in the kinase domain, which increases kinase activity ~2-3 fold. Other pathogenic mutations include:
- R1441C/G/H (ROC domain)
- Y1699C (COR domain)
- I2020T (kinase domain)
Pathogenic Mechanisms
Increased LRRK2 kinase activity causes:
- Excessive Rab protein phosphorylation
- Impaired autophagy and lysosomal clearance
- Mitochondrial dysfunction and impaired mitophagy
- Disrupted vesicle trafficking
- Enhanced susceptibility to alpha-synuclein toxicity
- Neuroinflammation via microglial activation
These converge on [dopaminergic neurons](/cell-types/dopaminergic-neurons) in the substantia nigra, causing their progressive loss—the hallmark of PD.
Clinical Features
LRRK2-associated PD is clinically similar to idiopathic PD:
- Asymmetric onset of motor symptoms (tremor, rigidity, bradykinesia)
- Good response to levodopa therapy
- Age of onset typically 50s-60s (range 30s-80s)
- Generally slower progression than sporadic PD
- Lower likelihood of cognitive impairment
Pathologically, most cases show classic Lewy body pathology with alpha-synuclein aggregates, though some show "pure" nigral degeneration without Lewy bodies.
Therapeutic Targeting
LRRK2 is one of the most promising drug targets in Parkinson's disease:
LRRK2 Kinase Inhibitors
Multiple selective LRRK2 kinase inhibitors are in clinical development:
- DNL201 (Denali Therapeutics) - Phase 1 completed
- DNL151 (Denali Therapeutics) - Phase 1b ongoing
- BIIB094 (Biogen) - Development discontinued
- Multiple preclinical compounds
These inhibitors aim to normalize hyperactive kinase activity. Key challenges include:
- Achieving CNS penetration
- Avoiding dose-limiting toxicity (lung abnormalities in primates)
- Determining optimal degree of kinase inhibition
Antisense Oligonucleotides
ASO-mediated reduction of LRRK2 expression is being explored as an alternative approach, particularly for mutation carriers.
Small Molecule Correctors
Compounds that normalize LRRK2 GTPase activity or prevent pathogenic interactions are in early research.
- [Parkinson's Disease](/diseases/parkinsons-disease) - Primary disease association
- [Alpha-Synuclein](/proteins/alpha-synuclein) - Interacts with LRRK2 pathways
- [Rab GTPases](/proteins/rab-gtpases) - Direct phosphorylation substrates
- [Dopaminergic Neurons](/cell-types/dopaminergic-neurons) - Primary vulnerable cell type
- [Autophagy](/mechanisms/autophagy) - Cellular process regulated by LRRK2
- [Microglia](/cell-types/microglia) - Express high LRRK2; role in neuroinflammation
References
Alessi DR, Sammler E. LRRK2 kinase in Parkinson's disease. Science. 2018;360(6384):36-37.
Steger M, et al. Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases. eLife. 2016;5:e12813.
Di Maio R, et al. LRRK2 activation in idiopathic Parkinson's disease. Sci Transl Med. 2018;10(451):eaar5429.
Tolosa E, et al. LRRK2 in Parkinson disease: challenges of clinical trials. Nat Rev Neurol. 2020;16(2):97-107.
Herbst S, Campbell P, et al. LRRK2 activation controls the repair of damaged endomembranes in macrophages. EMBO J. 2020;39(18):e104494.External Links
- [UniProt: LRRK2](https://www.uniprot.org/uniprot/Q5S007)
- [OMIM: LRRK2](https://www.omim.org/entry/609007)
- [Michael J. Fox Foundation: LRRK2](https://www.michaeljfox.org/understanding-parkinsons/living-with-pd/topic.php?genetics-lrrk2)
- [PubMed: LRRK2 therapeutics](https://pubmed.ncbi.nlm.nih.gov/?term=LRRK2+inhibitor+clinical)
Pathway Diagram
The following diagram shows the key molecular relationships involving LRRK2 (Leucine-Rich Repeat Kinase 2) discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)